Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
NIDA Research Monograph|January 1, 1988
Precipitation of spinally mediated withdrawal signs by intrathecal administration of naloxone and the mu-receptor antagonist CTP in morphine-dependent miceJ Shook, W Kazmierski, V Hruby, et al.
Peptides|July 1, 1987
Effects of a novel opioid peptide antagonist on rat bladder motility in vivoF Porreca, L Nunan, W Kazmierski, et al.
Bioorganic & Medicinal Chemistry Letters|January 2, 2001
A solid-phase approach to analogues of the antibiotic mureidomycinA Bozzoli, W Kazmierski, G Kennedy, et al.
European Journal of Pharmacology|November 15, 1988
Antagonist activity of the cyclic somatostatin analogue CTP at mu- but not delta- and kappa-opioid receptors involved in presynaptic inhibition of neurotransmitter releaseA H Mulder, G Wardeh, W Kazmierski, et al.
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|February 1, 1989
Structural characteristics of two highly selective opioid peptidesR J Knapp, W Kazmierski, V J Hruby, et al.
European Journal of Biochemistry|November 6, 1989
Conformation of two somatostatin analogues in aqueous solution. Study by NMR methods and circular dichroismC Wynants, D Tourwe, W Kazmierski, et al.
International Journal of Peptide and Protein Research|February 1, 1988
Proton n.m.r. investigation of conformational influence of penicillamine residues on the disulfide ring system of opioid receptor selective somatostatin derivativesE E Sugg, D Tourwe, W Kazmierski, et al.
Journal of Medicinal Chemistry|November 1, 1986
Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptorsJ T Pelton, W Kazmierski, K Gulya, et al.
International Journal of Peptide and Protein Research|October 1, 1990
Conformationally restricted analogs of oxytocin; stabilization of inhibitory conformationM Lebl, P Hill, W Kazmierski, et al.
European Journal of Pharmacology|November 19, 1991
Cyclic somatostatin analogues as potent antagonists at mu-, but not delta- and kappa-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the brainA H Mulder, G Wardeh, F Hogenboom, et al.
Pageof 2